Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value
$26.47−2.60 (-8.94%)
Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –
Zymeworks EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Zymeworks's EPS for the twelve months ending Sep 30, 2026 was $0.52. For fiscal 2025 it was -$1.08. The highest annual figure on record is $1.90 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.08 | – |
| FY2024 | Dec 31, 2024 | -$1.62 | – |
| FY2023 | Dec 31, 2023 | -$1.72 | -190.5% |
| FY2022 | Dec 31, 2022 | $1.90 | – |
| FY2021 | Dec 31, 2021 | -$4.61 | – |
| FY2020 | Dec 31, 2020 | -$3.58 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.28 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.62 | -2166.7% |
| Q1 FY2026 | Mar 31, 2026 | -$0.59 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.55 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.26 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.03 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.30 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.31 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.39 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.49 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.42 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.20 | -104.3% |
| Q3 FY2023 | Sep 30, 2023 | -$0.41 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.76 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.37 | – |
| Q4 FY2022 | Dec 31, 2022 | $4.64 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.72 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.97 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.19 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.75 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.25 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?